论文部分内容阅读
目的:分析曲美他嗪对尿毒症伴心肌病患者的临床疗效。方法:选取2015年4月—2016年6月间收治的尿毒症伴心肌病患者80例的临床资料,将其随机分为单一组40例与结合组40例;单一组患者均给予腹膜透析及血液透析等治疗,结合组患者则在单一组患者基础上加用曲美他嗪治疗,比较两组患者临床治疗后的总有效率及治疗期间不良反应的发生率。结果:结合组患者临床治疗后的总有效率明显好于单一组(P<0.05);不良反应的发生率低于单一组(P<0.05)。结论:尿毒症伴心肌病患者在腹膜透析及血液透析基础上,加用曲美他嗪治疗的临床疗效果较佳。
Objective: To analyze the clinical efficacy of trimetazidine in uremic patients with cardiomyopathy. Methods: The clinical data of 80 patients with uremia and cardiomyopathy admitted from April 2015 to June 2016 were selected and randomly divided into single group (40 cases) and combination group (40 cases). All patients in one group were given peritoneal dialysis and Hemodialysis and other treatments. Patients in combination group were treated with trimetazidine on the basis of a single group. The total effective rate after treatment and the incidence of adverse reactions during the treatment were compared between the two groups. Results: The total effective rate of the combination group was significantly better than that of the single group (P <0.05). The incidence of adverse reactions was lower than that of the single group (P <0.05). Conclusion: Patients with uremia and cardiomyopathy on the basis of peritoneal dialysis and hemodialysis, plus trimetazidine treatment of clinical efficacy is better.